Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer
International Journal of Cancer · 01.09.2026 · 159 (5) · 1124-1138
DOI: 10.1002/ijc.70522 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 04.05.2026. Verfasst von Monika Bar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Drug Resistance, Neoplasm, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 134 Literaturangaben. Gefördert von: the National Science Center, Poland.
Abstract (Originalsprache)
Breast cancer (BC) is the most commonly diagnosed tumor among women worldwide. Approximately 70% of cases are estrogen receptor‐positive (ER+), whose growth is driven by estrogen signaling. Endocrine therapies targeting ER signaling are the common treatment for ER+ disease; however, both intrinsic and acquired endocrine resistance continue to be a major clinical challenge. A growing body of evidence indicates that multiple coregulators influence ER recruitment to its genomic binding sites and tumor growth. Their aberrant expression can promote ligand‐independent ER activation and attenuate the effectiveness of ER‐targeted therapies. Consequently, targeting ERα coregulators has emerged as a promising therapeutic strategy to overcome endocrine resistance. In this review, we synthesize current evidence defining the roles of ERα coregulators in endocrine resistance, critically assess their therapeutic potential, and provide prioritization guidance for clinical development. A deeper understanding of the molecular mechanisms underpinning endocrine resistance is essential to improve treatment outcomes for patients with ER+ BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
ORCID-Profile: Monika Bar, Wiesława Widłak, Natalia Vydra
Förderung
- the National Science Center, Poland
Zitieren
APA
Bar, M., Widłak, W., & Vydra, N. (2026). Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer. International Journal of Cancer, 159(5), 1124-1138. https://doi.org/10.1002/ijc.70522
Vancouver
Bar M, Widłak W, Vydra N. Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer. International Journal of Cancer. 2026;159(5):1124-1138. doi:10.1002/ijc.70522
BibTeX
@article{Bar2026,
author = {Bar, Monika and Widłak, Wiesława and Vydra, Natalia},
title = {Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {5},
pages = {1124--1138},
doi = {10.1002/ijc.70522}
}
EUVIMED